<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01638390</url>
  </required_header>
  <id_info>
    <org_study_id>VISUMAX-2012-1</org_study_id>
    <nct_id>NCT01638390</nct_id>
  </id_info>
  <brief_title>Use of the VisuMax™ Femtosecond Laser</brief_title>
  <official_title>Use of the VisuMax™ Femtosecond Laser Lenticule Removal Procedure for the Correction of Myopia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carl Zeiss Meditec, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carl Zeiss Meditec, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical trial is to evaluate the safety and effectiveness of the Carl
      Zeiss Meditec VisuMax™ Femtosecond Laser lenticule removal procedure for the reduction or
      elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE (Manifest
      Refractive Spherical Equivalent) ≤ -8.25 D.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective multi-center clinical trial in which a total of 360 eyes of consecutive
      subjects will be enrolled, treated with the VisuMax™ Femtosecond Laser, and followed for a
      12-month period. The study will be conducted at up to 8 clinical sites.

      Enrollment will be phased such that 100 eyes will be initially enrolled and followed. When 50
      of the initial eyes have reached the 3-month follow-up exam, an interim clinical study report
      will be submitted to FDA along with a request to continue enrollment up to 360 eyes.

      Subjects will be screened for eligibility, and informed consent will be obtained from those
      who meet screening criteria and are interested in participating in the study. Eligible
      subjects will be examined preoperatively to obtain a medical history and to establish a
      baseline ocular condition. Baseline and postoperative measurements will include manifest
      refraction, cycloplegic refraction, distance visual acuity (best corrected and uncorrected),
      slit-lamp examination, fundus examination, corneal topography, central corneal pachymetry,
      mesopic pupil measurement, wavefront analysis, mesopic contrast sensitivity, and intraocular
      pressure (IOP).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness- Predictability</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants with a decrease in manifest refraction spherical equivalent (MRSE) to within ± 1.00 D and ± 0.50 D of the intended refractive outcome at the point at which stability is first reached. The MRSE is the amount of prescription needed to obtain your best corrected vision as compared to your preoperative best corrected vision. A minimum of 75% of eyes should have an achieved refraction within ± 1.00 D of the intended outcome, and at least 50% of eyes should be within ± 0.50 D of the intended outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effectiveness- Improvement in UCVA Following Treatment</measure>
    <time_frame>12 month</time_frame>
    <description>Number of participants with uncorrected visual acuity (UCVA) of 20/40 or better at the point of stability. .This is vision without any form of prescription. A target of 85% of participants is required.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stability Criteria- Change Between Visits Within 1.00 Diopter (D)</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with a change in postoperative refraction within 1.00 D between the 3 and 6 month visits. Stability was identified at the 6 month visit for the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety- Preservation of Best-Spectacle Corrected Visual Acuity (BSCVA)</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants with worse than 20/40 visual acuity with a preoperative BSCVA (Best Spectacle Corrected Visual Acuity) 20/20 or better. Target is less than 1% of study participants.
Less than 5% of participants with BCVA loss ≥ 2 lines</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety- Induced Manifest Refractive Astigmatism</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants with an increase of astigmatism of greater than 2.00 D cylinder from the preoperative values. Target is less than 5% of participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety- Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants for each type of adverse event. Target of less than 1% of participants for each type of adverse event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety- Contrast Sensitivity</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants who increased, remained the same, and decreased in contrast sensitivity. There are 4 different frequencies (1.5, 3.0, 6.0, and 12.0) which will be tested and are more difficult to detect as the frequency number increases.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stability Criteria- Change Between Visits Within 0.50 Diopter (D)</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with a change in postoperative refraction within 0.50 D between the 3 and 6 month visits. Stability was identified at the 6 month visit for the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety- Patient Symptoms</measure>
    <time_frame>12 months</time_frame>
    <description>A standardized quality of vision (QoV) questionnaire was used in the study. A score is generated and was used to compare the results from baseline to the 12 month visit. Number of participants who improved, stayed the same, or worsened with regards to the frequency, severity, and bothersomeness of symptoms are reported.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">357</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>Treatment of Myopia</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE ≤ -8.25 D.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Treatment with the VisuMax™ Femtosecond Laser</intervention_name>
    <description>The reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE ≤ -8.25 D.</description>
    <arm_group_label>Treatment of Myopia</arm_group_label>
    <other_name>VisuMaxTM Femtosecond Laser</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects age 22 years of age and older;

          -  Spherical myopia from ≥ -1.00 D to ≤ -8.00 D, with ≤ -0.50 D cylinder and MRSE ≤ -8.25
             D in the eye to be treated;

          -  A stable refraction for the past year, as demonstrated by a change in MRSE of ≤ 0.50 D
             in the eye to be treated;

          -  A difference between cycloplegic and manifest refractions of &lt; 0.75 D spherical
             equivalent in the eye to be treated;

          -  UCVA worse than 20/40 in the eye to be treated;

          -  BSCVA at least 20/20 in the eye to be treated;

          -  Discontinue use of contact lenses for at least 2 weeks (for hard lenses) or 3 days
             (for soft lenses) prior to the preoperative examination, and through the day of
             surgery;

          -  All contact lens wearers must demonstrate a stable refraction (within ±0.5 D), as
             determined by MRSE, on two consecutive examinations at least 1 week apart, in the eye
             to be treated;

          -  Central corneal thickness of at least 500 microns in the eye to be treated;

          -  Willing and able to return for scheduled follow-up examinations;

          -  Able to provide written informed consent and follow study instructions in English.

        Exclusion Criteria:

          -  Mesopic pupil diameter &gt; 8.0 mm;

          -  Cylinder &gt; -0.50 D;

          -  Treatment depth is less than 250 microns from the corneal endothelium;

          -  Eye to be treated is targeted for monovision;

          -  Fellow eye has BSCVA worse than 20/40;

          -  Abnormal corneal topographic findings, e.g. keratoconus, pellucid marginal
             degeneration in either eye;

          -  History of or current anterior segment pathology, including cataracts in the eye to be
             treated;

          -  Clinically significant dry eye syndrome unresolved by treatment in either eye;

          -  Residual, recurrent, active ocular or uncontrolled eyelid disease, corneal scars or
             other corneal abnormality such as recurrent corneal erosion or severe basement
             membrane disease in the eye to be treated;

          -  Ophthalmoscopic signs of progressive or unstable myopia or keratoconus (or keratoconus
             suspect) in either eye;

          -  Irregular or unstable (distorted/not clear) corneal mires on central keratometry
             images in either eye;

          -  History of ocular herpes zoster or herpes simplex keratitis;

          -  Deep orbits, strong blink, anxiety, pterygium, or any other finding suggesting
             difficulty in achieving or maintaining suction;

          -  Difficulty following directions or unable to fixate;

          -  Previous intraocular or corneal surgery of any kind in the eye to be treated,
             including any type of surgery for either refractive or therapeutic purposes;

          -  History of steroid-responsive rise in intraocular pressure, glaucoma, or preoperative
             IOP &gt; 21 mmHg in either eye;

          -  History of diabetes, diagnosed autoimmune disease, connective tissue disease or
             clinically significant atopic syndrome;

          -  Immunocompromised or requires chronic systemic corticosteroids or other
             immunosuppressive therapy that may affect wound healing;

          -  History of known sensitivity to planned study medications;

          -  Participating in any other ophthalmic drug or device clinical trial during the time of
             this clinical investigation;

          -  Pregnant, lactating, or of child-bearing potential and not practicing a medically
             approved method of birth control.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon Dishler, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dishler Laser Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Doane, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Discover Vision Centers</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vance Thompson, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vance Thompson Vision Clinic, Prof., LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Culbertson, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bascom Palmer Eye Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sonia Yoo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bascom Palmer Eye Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Vukich, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Davis Duehr Dean</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dishler Laser Institute</name>
      <address>
        <city>Greenwood Village</city>
        <state>Colorado</state>
        <zip>80111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bascom Palmer Eye Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Discover Vision Centers</name>
      <address>
        <city>Leawood</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vance Thompson Vision</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Davis Duehr Dean</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53717</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>July 2, 2012</study_first_submitted>
  <study_first_submitted_qc>July 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2012</study_first_posted>
  <results_first_submitted>May 2, 2018</results_first_submitted>
  <results_first_submitted_qc>December 12, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 21, 2019</results_first_posted>
  <last_update_submitted>December 12, 2018</last_update_submitted>
  <last_update_submitted_qc>December 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment of Myopia</title>
          <description>The reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE ≤ -8.25 D.
Treatment with the VisuMax™ Femtosecond Laser: The reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE ≤ -8.25 D.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="357">enrolled</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="336">treated eyes</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>screening failures</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment of Myopia</title>
          <description>The reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE ≤ -8.25 D.
Treatment with the VisuMax™ Femtosecond Laser: The reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE ≤ -8.25 D.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="336"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.33" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="196"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>white</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Surgical Eye</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>right</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>left</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effectiveness- Predictability</title>
        <description>Number of participants with a decrease in manifest refraction spherical equivalent (MRSE) to within ± 1.00 D and ± 0.50 D of the intended refractive outcome at the point at which stability is first reached. The MRSE is the amount of prescription needed to obtain your best corrected vision as compared to your preoperative best corrected vision. A minimum of 75% of eyes should have an achieved refraction within ± 1.00 D of the intended outcome, and at least 50% of eyes should be within ± 0.50 D of the intended outcome.</description>
        <time_frame>12 months</time_frame>
        <population>The number reflected at the 12 month visit is the effectiveness population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment of Myopia</title>
            <description>The reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE ≤ -8.25 D.
Treatment with the VisuMax™ Femtosecond Laser: The reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE ≤ -8.25 D.</description>
          </group>
        </group_list>
        <measure>
          <title>Effectiveness- Predictability</title>
          <description>Number of participants with a decrease in manifest refraction spherical equivalent (MRSE) to within ± 1.00 D and ± 0.50 D of the intended refractive outcome at the point at which stability is first reached. The MRSE is the amount of prescription needed to obtain your best corrected vision as compared to your preoperative best corrected vision. A minimum of 75% of eyes should have an achieved refraction within ± 1.00 D of the intended outcome, and at least 50% of eyes should be within ± 0.50 D of the intended outcome.</description>
          <population>The number reflected at the 12 month visit is the effectiveness population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MRSE, Attempted vs. Achieved, ±0.50 D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MRSE, Attempted vs. Achieved, ±1.00 D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effectiveness- Improvement in UCVA Following Treatment</title>
        <description>Number of participants with uncorrected visual acuity (UCVA) of 20/40 or better at the point of stability. .This is vision without any form of prescription. A target of 85% of participants is required.</description>
        <time_frame>12 month</time_frame>
        <population>The number reflected at the 12 month visit is the effectiveness population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment of Myopia</title>
            <description>The reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE ≤ -8.25 D.</description>
          </group>
        </group_list>
        <measure>
          <title>Effectiveness- Improvement in UCVA Following Treatment</title>
          <description>Number of participants with uncorrected visual acuity (UCVA) of 20/40 or better at the point of stability. .This is vision without any form of prescription. A target of 85% of participants is required.</description>
          <population>The number reflected at the 12 month visit is the effectiveness population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Stability Criteria- Change Between Visits Within 1.00 Diopter (D)</title>
        <description>Number of participants with a change in postoperative refraction within 1.00 D between the 3 and 6 month visits. Stability was identified at the 6 month visit for the study.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment of Myopia</title>
            <description>Participants within 1.00 D change</description>
          </group>
        </group_list>
        <measure>
          <title>Stability Criteria- Change Between Visits Within 1.00 Diopter (D)</title>
          <description>Number of participants with a change in postoperative refraction within 1.00 D between the 3 and 6 month visits. Stability was identified at the 6 month visit for the study.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="327"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety- Preservation of Best-Spectacle Corrected Visual Acuity (BSCVA)</title>
        <description>Number of participants with worse than 20/40 visual acuity with a preoperative BSCVA (Best Spectacle Corrected Visual Acuity) 20/20 or better. Target is less than 1% of study participants.
Less than 5% of participants with BCVA loss ≥ 2 lines</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment of Myopia</title>
            <description>The reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE ≤ -8.25 D</description>
          </group>
        </group_list>
        <measure>
          <title>Safety- Preservation of Best-Spectacle Corrected Visual Acuity (BSCVA)</title>
          <description>Number of participants with worse than 20/40 visual acuity with a preoperative BSCVA (Best Spectacle Corrected Visual Acuity) 20/20 or better. Target is less than 1% of study participants.
Less than 5% of participants with BCVA loss ≥ 2 lines</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="336"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BSCVA worse than 20/40 if 20/20 or better preopera</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of ≥ 2 lines BSCVA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety- Induced Manifest Refractive Astigmatism</title>
        <description>Number of participants with an increase of astigmatism of greater than 2.00 D cylinder from the preoperative values. Target is less than 5% of participants.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment of Myopia</title>
            <description>The reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE ≤ -8.25 D</description>
          </group>
        </group_list>
        <measure>
          <title>Safety- Induced Manifest Refractive Astigmatism</title>
          <description>Number of participants with an increase of astigmatism of greater than 2.00 D cylinder from the preoperative values. Target is less than 5% of participants.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="336"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety- Adverse Events</title>
        <description>Number of participants for each type of adverse event. Target of less than 1% of participants for each type of adverse event.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment of Myopia</title>
            <description>Reported Adverse Events</description>
          </group>
        </group_list>
        <measure>
          <title>Safety- Adverse Events</title>
          <description>Number of participants for each type of adverse event. Target of less than 1% of participants for each type of adverse event.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="336"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Retinal vasculitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Carcinoma in situ, conjunctival</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decrease in BSCVA of ≥ 2 lines (≥10 letters) not d</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conjunctivitis, allergic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conjunctivitis, viral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Herpetic lid and corneal lesion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Iritis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>posterior vitreous detachment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pyogenic Granuloma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Retained tissue, small</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difficult lenticule removal with tissue damage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety- Contrast Sensitivity</title>
        <description>Number of participants who increased, remained the same, and decreased in contrast sensitivity. There are 4 different frequencies (1.5, 3.0, 6.0, and 12.0) which will be tested and are more difficult to detect as the frequency number increases.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment of Myopia</title>
            <description>Change in contrast sensitivity</description>
          </group>
        </group_list>
        <measure>
          <title>Safety- Contrast Sensitivity</title>
          <description>Number of participants who increased, remained the same, and decreased in contrast sensitivity. There are 4 different frequencies (1.5, 3.0, 6.0, and 12.0) which will be tested and are more difficult to detect as the frequency number increases.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Gained at greater than or equal to 2 frequencies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss at greater than or equal to 2 frequencies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Stability Criteria- Change Between Visits Within 0.50 Diopter (D)</title>
        <description>Number of participants with a change in postoperative refraction within 0.50 D between the 3 and 6 month visits. Stability was identified at the 6 month visit for the study.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment of Myopia</title>
            <description>Participants within 0.50 D change</description>
          </group>
        </group_list>
        <measure>
          <title>Stability Criteria- Change Between Visits Within 0.50 Diopter (D)</title>
          <description>Number of participants with a change in postoperative refraction within 0.50 D between the 3 and 6 month visits. Stability was identified at the 6 month visit for the study.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="327"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety- Patient Symptoms</title>
        <description>A standardized quality of vision (QoV) questionnaire was used in the study. A score is generated and was used to compare the results from baseline to the 12 month visit. Number of participants who improved, stayed the same, or worsened with regards to the frequency, severity, and bothersomeness of symptoms are reported.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment of Myopia</title>
            <description>Quality of Vision Score Change from Preoperative</description>
          </group>
        </group_list>
        <measure>
          <title>Safety- Patient Symptoms</title>
          <description>A standardized quality of vision (QoV) questionnaire was used in the study. A score is generated and was used to compare the results from baseline to the 12 month visit. Number of participants who improved, stayed the same, or worsened with regards to the frequency, severity, and bothersomeness of symptoms are reported.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Frequency</title>
              <category_list>
                <category>
                  <title>worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                  </measurement_list>
                </category>
                <category>
                  <title>same</title>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity</title>
              <category_list>
                <category>
                  <title>worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                  </measurement_list>
                </category>
                <category>
                  <title>same</title>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                  </measurement_list>
                </category>
                <category>
                  <title>improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bothersome</title>
              <category_list>
                <category>
                  <title>worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>same</title>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                  </measurement_list>
                </category>
                <category>
                  <title>improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>approximately 2 years, 11 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment of Myopia</title>
          <description>The reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE ≤ -8.25 D.
Treatment with the VisuMax™ Femtosecond Laser: The reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE ≤ -8.25 D.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="336"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="336"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="336"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Decrease in BSCVA of greater than or equal to 2 lines</sub_title>
                <description>A decrease in best spectacle corrected visual acuity (BSCVA) of greater than or equal to 2 lines not due to irregular astigmatism as shown by hard contact lens refraction at 3 months or later</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
              </event>
              <event>
                <sub_title>Viral conjunctivitis</sub_title>
                <description>An inflammatory process of the conjunctiva due a virus.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
              </event>
              <event>
                <sub_title>Retinal vasculitis</sub_title>
                <description>A retinal blood vessel inflammation seen inside the eye.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
              </event>
              <event>
                <sub_title>Conjunctival carcinoma in situ</sub_title>
                <description>A cancerous growth on the conjunctiva.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
              </event>
              <event>
                <sub_title>Allergic conjunctivitis</sub_title>
                <description>an inflammatory process of the conjunctiva due to an allergen.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
              </event>
              <event>
                <sub_title>Difficult lenticule removal with tissue damage</sub_title>
                <description>During the surgical procedure, the process of removing the lenticule caused damage to the cornea around the incision site.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="336"/>
              </event>
              <event>
                <sub_title>Herpetic lid and corneal lesion</sub_title>
                <description>A lid lesion and a corneal finding associated with the herpes virus.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
              </event>
              <event>
                <sub_title>Iritis</sub_title>
                <description>An inflammatory process of the iris.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
              </event>
              <event>
                <sub_title>Posterior vitreous detachment</sub_title>
                <description>The gel within the eye starts to change consistency and starts to constrict within the eye.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
              </event>
              <event>
                <sub_title>Perforated cap</sub_title>
                <description>During the surgical process, a hole was created in the corneal flap during the lenticule removal process.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
              </event>
              <event>
                <sub_title>Pyogenic granuloma</sub_title>
                <description>A non-cancerous growth on the lower lid.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
              </event>
              <event>
                <sub_title>Retained tissue</sub_title>
                <description>During the surgical process, a small amount of tissue was retained which was seen on observation.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="336"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Todd Otani, Senior Clinical Research Scientist</name_or_title>
      <organization>Carl Zeiss Meditec, Inc.</organization>
      <phone>925-557-4513</phone>
      <email>todd.otani@zeiss.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

